PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis to 2022

Publisher Name :
Date: 31-May-2013
No. of pages: 140

Summary

GlobalData has released its new Country report, “PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis to 2022″. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. GlobalData expects a dramatic shift favoring the uptake of interferon-free regimens due to their more tolerable side-effect profiles and decreased duration of therapy compared with the current standard of care.

The projected drivers of market growth include increased patient awareness of HCV, broader HCV screening recommendations, the shift in American medicine toward preventative care, and the launch of next-generation HCV therapies.

Vertex’s Incivek is the current market leader. It was among the first DAA HCV therapies launched in the US. Incivek’s improved efficacy over the previous standard of care (i.e., peginterferon and ribavirin combination therapy) in the treatment of the most prevalent HCV genotype in the US, HCV GT1, enabled the drug to quickly capture the market. The adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.

Scope

  • Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US HCV market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for HCV
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in the US

PharmaPoint: Hepatitis C Virus – United States Drug Forecast and Market Analysis to 2022

Table Of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
2.3 Upcoming Related Reports 11

3 Disease Overview 12
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Prognosis 17
3.2 Symptoms 17

4 Disease Management 18
4.1 Diagnosis and Referral Overview 18
4.2 Treatment Overview 19
4.3 US 22
4.3.1 Diagnosis 22
4.3.2 Clinical Practice 24

5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 27
5.3 Product Profiles - Major Brands 29
5.3.1 Incivek (telaprevir) 29
5.3.2 Victrelis (boceprevir) 34
5.3.3 Pegasys (peginterferon alfa-2a) 38
5.3.4 PegIntron (peginterferon alfa-2b) 43
5.3.5 Copegus, Rebetol, and Generic Ribavirin 47
5.3.6 Therapeutic Class: Interferon 50

6 Opportunity and Unmet Need 51
6.1 Overview 51
6.2 Unmet Needs 52
6.2.1 Unmet Need: Treatment Tolerability 52
6.2.2 Unmet Need: Efficacy 52
6.2.3 Unmet Need: Disease Awareness 53
6.2.4 Unmet Need: Treatment Cost 54
6.2.5 Unmet Need: Shorter Treatment Duration 54
6.2.6 Unmet Need: Simplified Treatment Regimens 55
6.3 Unmet Needs Gap Analysis 56
6.4 Opportunities 57
6.4.1 Opportunity: Pan-genotypic HCV Regimen 57
6.4.2 Opportunity: Treatment of Underrepresented Patient Populations 57
6.4.3 Opportunity: Involvement of Immune System 58

7 Pipeline Assessment 59
7.1 Overview 59
7.2 Promising Drugs in Clinical Development 60
7.2.1 Sofosbuvir and Sofosbuvir/Ledipasvir 62
7.2.2 Simeprevir 72
7.2.3 ABT-450 plus ABT-267 and ABT-333 80
7.2.4 Faldaprevir and Faldaprevir plus BI 207127 87
7.2.5 Daclatasvir and Daclatasvir plus Asunaprevir 95
7.2.6 Other Drug Classes 103

8 Market Outlook 106
8.1 US 106
8.1.1 Forecast 106
8.1.2 Key Events 111
8.1.3 Drivers and Barriers 111

9 Appendix 116
9.1 Bibliography 116
9.2 Abbreviations 125
9.3 Methodology 127
9.4 Forecasting Methodology 127
9.4.1 Percent Drug-Treated Patients 127
9.4.2 Patient Warehousing 128
9.4.3 Drugs Included in Each Therapeutic Class 128
9.4.4 Launch and Patent Expiry Dates 129
9.4.5 General Pricing Assumptions 130
9.4.6 Individual Drug Assumptions 130
9.4.7 Generic Erosion 132
9.4.8 Selection of Pipeline Agents 132
9.4.9 Pricing of Pipeline Agents 133
9.5 Physicians and Specialists Included in this Study 136
9.6 Survey of Prescribing Physicians 138
9.7 About the Authors 139
9.7.1 Author 139
9.7.2 Global Head of Healthcare 139
9.8 About GlobalData 140
9.9 Contact Us 140
9.10 Disclaimer 140

List Of Tables

Table 1: Modes of HCV Transmission 16
Table 2: Symptoms of Acute and Chronic HCV Infection 17
Table 3: HCV Genotypes Present in the 9MM 19
Table 4: General Standard of Care by HCV Genotype 19
Table 5: Treatment Guidelines for HCV by Country 21
Table 6: Most-Prescribed Drugs for HCV by Class in the Global Markets, 2013 21
Table 7: Leading Treatments for HCV, 2012 28
Table 8: Product Profile - Incivek 30
Table 9: Efficacy of Incivek in Treatment-Naïve Patients (ADVANCE Trial) 30
Table 10: Efficacy of Incivek in Treatment-Experienced Patients (REALIZE Trial) 31
Table 11: Common Incivek Adverse Drug Reactions 32
Table 12: Incivek SWOT Analysis, 2012 33
Table 13: Product Profile - Victrelis 34
Table 14: Victrelis Efficacy in Treatment-Naïve Patients (SPRINT-2 Trial) 35
Table 15: Victrelis Efficacy in Treatment-Experienced Patients (RESPOND-2 Trial) 36
Table 16: Victrelis SWOT Analysis, 2012 37
Table 17: Product Profile - Pegasys 39
Table 18: Antiviral Efficacy of Peginterferon alfa-2a Compared with Interferon alfa-2b 40
Table 19: Pegasys SWOT Analysis, 2012 42
Table 20: Product Profile - PegIntron 44
Table 21: Antiviral Efficacy of Peginterferon alfa-2b Compared with Interferon alfa-2b 44
Table 22: PegIntron SWOT Analysis, 2012 46
Table 23: Effect of Addition of Ribavirin to Peginterferon HCV Therapy 48
Table 24: Ribavirin SWOT Analysis, 2012 49
Table 25: Summary of Minor Therapeutic Classes, 2012 50
Table 26: Overall Unmet Needs - Current Level of Attainment 51
Table 27: Clinical Unmet Needs - Gap Analysis, 2012 56
Table 28: HCV - Pipeline, 2012 60
Table 29: Comparison of Therapeutic Classes in Development for HCV, 2012 61
Table 30: Gilead's Sofosbuvir Ongoing Clinical Trials of Interest 63
Table 31: Product Profile - Sofosbuvir 64
Table 32: Sofosbuvir's Most Common Adverse Effects 67
Table 33: Sofosbuvir SWOT Analysis, 2012 71
Table 34: Janssen's Simeprevir Ongoing Clinical Trials of Interest 73
Table 35: Product Profile - Simeprevir 74
Table 36: PILLAR Clinical Trial Results 74
Table 37: Adverse Events Observed in PILLAR Clinical Trial 75
Table 38: Simeprevir SWOT Analysis, 2012 79
Table 39: AbbVie's Combination Therapy Ongoing Clinical Trials of Interest 81
Table 40: Product Profile - AbbVie Combination Therapy 82
Table 41: AVIATOR Clinical Trial Results 82
Table 42: AbbVie Combination Therapy SWOT Analysis, 2012 86
Table 43: Boehringer Ingelheim's Faldaprevir Ongoing Clinical Trials of Interest 88
Table 44: Product Profile - Faldaprevir 89
Table 45: Efficacy of Interferon-Free Faldaprevir Regimen (SOUND-C2 Trial) 89
Table 46: Faldaprevir SWOT Analysis, 2012 94
Table 47: Bristol-Myers Squibb's Daclatasvir Ongoing Clinical Trials of Interest 96
Table 48: Product Profile - Daclatasvir 97
Table 49: Efficacy of Daclatasvir in Treatment-Naïve Patients (COMMAND-1 Trial) 97
Table 50: Daclatasvir and Asunaprevir Quad Therapy Efficacy 98
Table 51: Daclatasvir Triple Therapy Adverse Events 99
Table 52: Daclatasvir SWOT Analysis, 2012 102
Table 53: Comparison of Peginterferon lambda with Peginterferon alfa (EMERGE Trial) 103
Table 54: Efficacy of Alisporivir in Treatment-Naïve HCV GT2/3 Patients (VITAL-1 Trial) 104
Table 55: Sales Forecasts ($m) for HCV in the US, 2012-2022 109
Table 56: Key Events Impacting Sales for HCV in the US, 2012 111
Table 57: US HCV Market - Drivers and Barriers, 2012 111
Table 58: Key Launch Dates 129
Table 59: Key Patent Expiries 129
Table 60: Physicians Surveyed, By Country 138

List Of Figures

Figure 1: HCV Genome and Polyprotein Composition 13
Figure 2: HCV Lifecycle Overview 14
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HCV, 2012-2022 60
Figure 4: Sales for HCV Therapeutics in the US by Drug Class, 2012-2022 110

  • Global Epilepsy Drug Market Continues to Grow Steadily
    The global epilepsy drug market has grown steadily in recent years with increased sales of anti-epileptic drugs which are targeted at reducing seizures. Epilepsy is a condition which affects the brain and is characterized with repeated seizures in the patient. Treatment for epilepsy usually involves the use of medicines known as anti-epileptic drugs which prevents [...]
  • Global Meat and Poultry Product Market to Witness Steady Growth
    As global demand for meat and poultry products continues to rise, the market for meat and poultry is also expected to grow steadily. The market for meat and poultry products is driven by rise in disposable income, growing awareness among consumers about the importance of adding protein to their diet, and change in eating habits. [...]
  • Global Budget Hotel Market Driven by Increase in Business Travel
    In the aftermath of the global economic crisis, the hotel industry had witnessed declining growth, particularly in the luxury hotel segment. However, in the past couple of year, the hotel market has recovered, bolstered by a rise in demand. With rise in disposable income in Asian countries, increase in business travel and growing demand for [...]
  • Global e-book Market Continues to Thrive with Growing Popularity of e-Readers and Tablets
    In recent years, there has been an unprecedented growth in the sale of e-books with more and more people taking to reading electronic books on e-book readers. The digitization of content and its delivery over the internet has changed the face of the book publishing market. While the market for print books is declining, the [...]
  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • EpiCast Report: Celiac Disease – Epidemiology Forecast to 2023
    Published: 12-Nov-2014        Price: US $3995 Onwards        Pages: 46
    Celiac disease is an autoimmune disease that occurs in individuals who consume gluten-containing foods but are intolerant to gluten, a protein found in many grains, such as wheat, rye, and barley. In celiac disease, the body’s immune system attacks and destroys the villi of the small intestine and thus interferes with nutrient absorption. Celiac disease can be difficult to diagnose because the symptoms vary between individuals and are non-specific, such as abdominal bloating and pain, diarrhea......
  • Russia: Antibiotics – Market Report. Analysis and Forecast to 2020
    Published: 10-Nov-2014        Price: US $1900 Onwards        
    "Report will be delivered within 3-4 working days" The report provides an in-depth analysis of the Russian Market of Antibiotics. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. The report shows the sales data, allowing you to identify the key drivers and restraints. You can find here a strategic analysis of key factors influencing the market. Forecasts illustrate how the market will be transfor......
  • Russia: Vaccines For Human Medicine – Market Report. Analysis and Forecast to 2020
    Published: 10-Nov-2014        Price: US $1900 Onwards        
    "Report will be delivered within 3-4 working days" The report provides an in-depth analysis of the Russian Market of Vaccines For Human Medicine. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. The report shows the sales data, allowing you to identify the key drivers and restraints. You can find here a strategic analysis of key factors influencing the market. Forecasts illustrate how the market ......
  • EU: Antibiotics – Market Report. Analysis and Forecast to 2020
    Published: 10-Nov-2014        Price: US $1900 Onwards        
    "Report will be delivered within 3-4 working days" The report provides an in-depth analysis of the EU Market of Antibiotics. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. The report shows the sales data, allowing you to identify the key drivers and restraints. You can find here a strategic analysis of key factors influencing the market. Forecasts illustrate how the market will be transformed i......
  • EU: Vaccines For Human Medicine – Market Report. Analysis and Forecast to 2020
    Published: 10-Nov-2014        Price: US $1900 Onwards        
    "Report will be delivered within 3-4 working days" The report provides an in-depth analysis of the EU Market of Vaccines For Human Medicine. It presents the latest data of the market size and volume, domestic production, exports and imports, price dynamics and turnover in the industry. The report shows the sales data, allowing you to identify the key drivers and restraints. You can find here a strategic analysis of key factors influencing the market. Forecasts illustrate how the market will ......
  • Global Prostate Cancer Drugs Market 2014-2018
    Published: 5-Nov-2014        Price: US $2500 Onwards        Pages: 71
    Prostate cancer initiates in the prostate, which is an exocrine gland present in the male reproductive system. The main function of the prostate is to make fluid for semen. The risk of developing prostate cancer is age dependent. Prostate cancer affects mostly men over the age of 65 and rarely occurs in men younger than 40 years of age. TechNavio's analysts forecast the Global Prostate Cancer Drugs market to grow at a CAGR of 10.45 percent over the period 2013-2018. Covered in this Report ......
  • Alzheimer’s Disease Drugs Markets in China
    Published: 1-Nov-2014        Price: US $4000 Onwards        Pages: 208
    China''s demand for Alzheimer''s Disease Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China''s economic trends, investment environment, industry development, supply and demand, industry ......
  • Antibiotics Markets in China
    Published: 1-Nov-2014        Price: US $4000 Onwards        Pages: 237
    China''s demand for Antibiotics has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China''s economic trends, investment environment, industry development, supply and demand, industry capacity, indus......
  • Incretion Drugs Markets in China
    Published: 1-Nov-2014        Price: US $4000 Onwards        Pages: 217
    China''s demand for Incretion Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China''s economic trends, investment environment, industry development, supply and demand, industry capacity, i......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs